» Articles » PMID: 25997541

The UBC-40 Urothelial Bladder Cancer Cell Line Index: a Genomic Resource for Functional Studies

Abstract

Background: Urothelial bladder cancer is a highly heterogeneous disease. Cancer cell lines are useful tools for its study. This is a comprehensive genomic characterization of 40 urothelial bladder carcinoma (UBC) cell lines including information on origin, mutation status of genes implicated in bladder cancer (FGFR3, PIK3CA, TP53, and RAS), copy number alterations assessed using high density SNP arrays, uniparental disomy (UPD) events, and gene expression.

Results: Based on gene mutation patterns and genomic changes we identify lines representative of the FGFR3-driven tumor pathway and of the TP53/RB tumor suppressor-driven pathway. High-density array copy number analysis identified significant focal gains (1q32, 5p13.1-12, 7q11, and 7q33) and losses (i.e. 6p22.1) in regions altered in tumors but not previously described as affected in bladder cell lines. We also identify new evidence for frequent regions of UPD, often coinciding with regions reported to be lost in tumors. Previously undescribed chromosome X losses found in UBC lines also point to potential tumor suppressor genes. Cell lines representative of the FGFR3-driven pathway showed a lower number of UPD events.

Conclusions: Overall, there is a predominance of more aggressive tumor subtypes among the cell lines. We provide a cell line classification that establishes their relatedness to the major molecularly-defined bladder tumor subtypes. The compiled information should serve as a useful reference to the bladder cancer research community and should help to select cell lines appropriate for the functional analysis of bladder cancer genes, for example those being identified through massive parallel sequencing.

Citing Articles

Epigenetic regulation in muscle-invasive urothelial carcinoma of the bladder in the dog, a translational model of human cancer.

Tsamouri M, Kent M, Mudryj M, Ghosh P Vet Oncol. 2025; 1.

PMID: 39944718 PMC: 11815638. DOI: 10.1186/s44356-024-00011-2.


Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery.

Mokkapati S, Manyam G, Steinmetz A, Tholomier C, Martini A, Choi W Transl Oncol. 2025; 52:102269.

PMID: 39808845 PMC: 11782912. DOI: 10.1016/j.tranon.2024.102269.


Loss of YTHDC1 mA reading function promotes invasiveness in urothelial carcinoma of the bladder.

Xu J, Koch J, Schmidt C, Nientiedt M, Neuberger M, Erben P Exp Mol Med. 2024; 57(1):118-130.

PMID: 39741187 PMC: 11799412. DOI: 10.1038/s12276-024-01377-x.


copy number alteration in bladder cancer: Integrative analysis in patient-derived xenografts and cancer patients.

Papadimitriou M, Pilala K, Panoutsopoulou K, Levis P, Kotronopoulos G, Kanaki Z Mol Ther Oncol. 2024; 32(2):200818.

PMID: 38966038 PMC: 11223115. DOI: 10.1016/j.omton.2024.200818.


Cepharanthine inhibits migration, invasion, and EMT of bladder cancer cells by activating the Rap1 signaling pathway in vitro.

Chen B, Chen L, Yang J, Hou M, Cai Q, Dai W Am J Transl Res. 2024; 16(5):1602-1619.

PMID: 38883391 PMC: 11170605. DOI: 10.62347/WDFF7432.


References
1.
Hurst C, Fiegler H, Carr P, Williams S, Carter N, Knowles M . High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004; 23(12):2250-63. DOI: 10.1038/sj.onc.1207260. View

2.
Pounds S, Cheng C, Mullighan C, Raimondi S, Shurtleff S, Downing J . Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics. 2008; 25(3):315-21. PMC: 2639073. DOI: 10.1093/bioinformatics/btn624. View

3.
Sarkar S, Julicher K, Burger M, Della Valle V, Larsen C, Yeager T . Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res. 2000; 60(14):3862-71. View

4.
Warenius H, Jones M, Gorman T, McLeish R, Seabra L, Barraclough R . Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer. 2000; 83(8):1084-95. PMC: 2363568. DOI: 10.1054/bjoc.2000.1409. View

5.
Blaveri E, Brewer J, Roydasgupta R, Fridlyand J, DeVries S, Koppie T . Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res. 2005; 11(19 Pt 1):7012-22. DOI: 10.1158/1078-0432.CCR-05-0177. View